Events

GPAI Paris w/ Joanna Shields

Our CEO Joanna Shields, joins international AI experts from civil society, academia, industry and government at the Global Partnership on Artificial Intelligence (GPAI) Summit in Paris.

This important occasion offers GPAI experts and member governments to showcase recent developments from GPAI working groups in order to discuss how their collective efforts can be best harnessed to advance the responsible development and utilization of AI.

Aiming to engage external partnerships as well, the public-facing event will include reporting on ten working group study topics from the 2021 work plan, as well as additional reflection sessions facilitated by France as the host country.

About GPAI

Launched in June 2020, GPAI ("gee-pay") is a multistakeholder initiative bringing together leading experts from science, industry, civil society, international organizations and government that share values to bridge the gap between theory and practice on AI by supporting cutting-edge research and applied activities on AI-related priorities.

GPAI aims to provide a mechanism for sharing multidisciplinary research and identifying key issues among AI practitioners, with the objective of facilitating international collaboration, reducing duplication, acting as a global reference point for specific AI issues, and ultimately promoting trust in and the adoption of trustworthy AI.

Through the collaboration within our working groups, GPAI assesses – on a comprehensive, objective, open, and transparent basis – the scientific, technical, and socio-economic information relevant to understanding AI impacts, encouraging its responsible development and options for adaptation and mitigation of potential challenges.

Watch the public conference live here →
More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022